John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses a randomized phase II study of regorafenib in refractory advanced oesophago-gastric cancer (AOGC).

Zalcberg says there was a significant improvement in progression-free survival (PFS) for patients who received regorafenib compared to placebo, with both arms receiving best supportive care. He and his team looked at Caucasian patients from Australia, New Zealand, and Canada compared to patients from Korea. The hazard ratio was .6 for the first group and .12 for the second.

Zalcberg and his colleagues hope to complete a phase III study in the near future, in order to define the benefit of regorafenib. Overall, the toxicities were not as significant as expected.

свернуть